http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3733208-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_758994071efb42b565fc2c04637be131 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-333 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-332 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-33337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L71-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-3322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-3328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-2609 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G65-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G65-333 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G65-332 |
| filingDate | 2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dd27a9deb0410d2f27748e05f3e1910 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47dfa89dfc86ed803078ae887c9b6f09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3c4a2bf7aa863ef4aa053b09a5c0949 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e41207dc8ae2ab3b6a5d5b30acd82549 |
| publicationDate | 2020-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3733208-A1 |
| titleOfInvention | Starting material for bulk drug or additives for drug, and bulk drug or drug using same |
| abstract | The present invention provides a raw material for bulk drugs and a pharmaceutical additive which provide excellent formulation stability and excellent over-time stability of drug efficacy when used to modify a bulk drug, a polypeptide, a bioactive protein, an enzyme, and the like. The present invention relates to a raw material for bulk drugs or a pharmaceutical additive, containing: a polyether composition (A) represented by formula (1), wherein the polyether composition (A) has a unimodal molecular weight distribution, the polyether composition (A) has a ratio (Mw/Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) of 1.20 or less, and the polyether composition (A) contains a compound in which m is 1 in formula (1) in an amount of 90 wt% or more based on the weight of the polyether composition (A), in formula (1), OR<sup>1</sup>, R<sup>2</sup>O, R<sup>3</sup>O, and R<sup>4</sup>O are each independently a C2-C8 oxyalkylene group; when each of these moieties exists in the plural number, each OR<sup>1</sup>, each R<sup>2</sup>O, each R<sup>3</sup>O, and each R<sup>4</sup>O may be the same as or different from each other; these moieties may be bonded randomly or in block; a, b, c, and d are each independently an integer of 50 to 1200; X<sup>1</sup>to X<sup>4</sup>are each independently a hydrogen atom, a substituent represented by formula (2), or a substituent represented by formula (3); and m is an integer of 1 to 10. |
| priorityDate | 2017-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 485.